Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$117.52

0.37 (0.32%)

19:16
12/07/19
12/07
19:16
12/07/19
19:16

Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data

Seattle Genetics announced updated and long-term follow-up analyses from two clinical trials evaluating Adcetris and Opdivo in frontline Hodgkin lymphoma patients aged 60 years and older and in relapsed or refractory classical HL. Results were presented today at the American Society of Hematology Annual Meeting. Data were reported from 21 patients, and the median age was 72 years. Of 19 response-evaluable patients, 18 patients had an objective response, including 13 patients with a complete response and five patients with a partial response. All response-evaluable patients experienced tumor reduction following treatment with Adcetris in combination with Opdivo. Median duration of response was not yet reached and the maximum duration of response was 22 months and ongoing, the company added. The most common treatment-related adverse events of any grade occurring in at least 20% of patients were fatigue, diarrhea, pyrexia, infusion related reaction, peripheral motor neuropathy, peripheral sensory neuropathy and increase in lipase.Data were reported from 93 patients with relapsed or refractory classical HL after failure of frontline therapy who received the combination regimen of Adcetris plus Opdivo. Of the 91 treated patients, 85 percent had an objective response, including 67% with a complete response, 16 patients with a partial response and six patients had stable disease. Of the 91 treated patients, 67 patients received an ASCT per trial protocol with no additional salvage therapy.

  • 07

    Dec

  • 15

    Mar

SGEN Seattle Genetics
$117.52

0.37 (0.32%)

10/22/19
RBCM
10/22/19
NO CHANGE
Target $109
RBCM
Outperform
Seattle Genetics price target raised to $109 from $80 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Seattle Genetics to $109 after the "unexpectedly impressive" phase 3 data of its tucatinib drug in patients with HER2-positive breast cancer. The analyst is boosting his breadth and depth forecasts for tucatinib across indications, also raising his market penetration estimates to 75% from 45% and modeling peak risk adjusted sales of $531M and $171M in respective U.S. and EU5 markets. MacKay is keeping his Outperform rating on Seattle Genetics.
10/22/19
LEER
10/22/19
NO CHANGE
Target $120
LEER
Outperform
Seattle Genetics price target raised to $120 from $102 at SVB Leerink
SVB Leerink analyst Andrew Berens raised his price target for Seattle Genetics to $120 from $102 following positive topline data from the pivotal HER2CLIMB trial for tucatinib. The analyst remains bullish on Seattle Genetics as a pipeline driven story, with positive momentum driven by enthusiasm for enfortumab vedotin in bladder cancer following strong data presented at ESMO, tucatinib HER2CLIMB success, which provides the company's first win in small molecules and a catalyst for a global footprint, and increasing confidence in the ADC + I/O synergy story, driving increased fundamental and strategic value for the ADC platform. He reiterates an Outperform rating on the shares.
10/29/19
PIPR
10/29/19
NO CHANGE
Target $120
PIPR
Overweight
Seattle Genetics price target raised to $120 from $95 at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro raised his price target on Seattle Genetics to $120 after its "modest" beat on Adcetris revenue in Q3 along with an upwardly narrowed outlook for FY19. The analyst notes that the company has an "additional opportunity" driven by the potential launch for its Enfortumab vedotin, or EV, in 3rd-line UBC in 2020, along with other opportunities across the pipeline over the near term. Catanzaro also keeps his Overweight rating on Seattle Genetics.
12/03/19
BOFA
12/03/19
INITIATION
Target $125
BOFA
Neutral
Seattle Genetics resumed with a Neutral at BofA/Merrill
BofA/Merrill analyst Geoff Meacham resumed coverage of Seattle Genetics with a Neutral rating and $125 price target. The analyst is positive on its growth prospects for Adcetris given the increased uptake in frontline peripheral T-cell lymphoma and potential immuno-oncology combos, as well as its de-risked pipeline assets that could launch in 2020. Meacham adds that the company's antibody-drug conjugate platform is unique and capable of generating more commercial products beyond its current pipeline. With a 107% year-to-date run-up however, the analyst contends that the stock accounts for these near-term opportunities while struggling with visibility on the earlier-stage assets.

TODAY'S FREE FLY STORIES

BT

BT Group

$0.00

(0.00%)

, GOOG

Alphabet

$1,461.36

9.42 (0.65%)

11:42
01/17/20
01/17
11:42
01/17/20
11:42
Hot Stocks
BT partners with Google to include Stadia in broadband bundles »

BT Group (BT) said via…

BT

BT Group

$0.00

(0.00%)

GOOG

Alphabet

$1,461.36

9.42 (0.65%)

GOOGL

Alphabet Class A

$1,459.67

9.84 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

PLAY

Dave & Buster's

$46.14

4.085 (9.71%)

11:39
01/17/20
01/17
11:39
01/17/20
11:39
Recommendations
Dave & Buster's analyst commentary  »

Stifel wouldn't be a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

FB

Facebook

$220.95

-0.83 (-0.37%)

11:37
01/17/20
01/17
11:37
01/17/20
11:37
Periodicals
Facebook cuts Oculus Go price to $149 from $199, UploadVR reports »

Facebook said that it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

WMT

Walmart

$115.15

-0.74 (-0.64%)

11:36
01/17/20
01/17
11:36
01/17/20
11:36
Hot Stocks
Walmart U.S. names Dacona Smith as incoming COO »

Walmart U.S. says Dacona…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

GOOGL

Alphabet Class A

$1,461.15

11.32 (0.78%)

, GOOG

Alphabet

$1,462.70

10.76 (0.74%)

11:33
01/17/20
01/17
11:33
01/17/20
11:33
Periodicals
Google working to bring Steam support to Chromebooks, Android Police says »

Kan Liu, director of…

GOOGL

Alphabet Class A

$1,461.15

11.32 (0.78%)

GOOG

Alphabet

$1,462.70

10.76 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

WMT

Walmart

$115.30

-0.59 (-0.51%)

11:28
01/17/20
01/17
11:28
01/17/20
11:28
Periodicals
Walmart chief merchant Steve Bratspies to depart, WSJ reports »

Walmart chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

NFLX

Netflix

$339.15

0.48 (0.14%)

11:25
01/17/20
01/17
11:25
01/17/20
11:25
Hot Stocks
Netflix opens new Paris office, boosts investment in France »

Netflix announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

11:25
01/17/20
01/17
11:25
01/17/20
11:25
General news
Philly Fed's Harker said the economy is looking "pretty good," »

Philly Fed's Harker…

AMED

Amedisys

$180.60

-0.59 (-0.33%)

11:25
01/17/20
01/17
11:25
01/17/20
11:25
Conference/Events
Amedisys participates in a conference call with Benchmark »

Healthcare Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

IBM

IBM

$137.15

-0.85 (-0.62%)

, PINS

Pinterest

$23.11

0.15 (0.65%)

11:24
01/17/20
01/17
11:24
01/17/20
11:24
On The Fly
IBM downgrade, Pinterest upgrade among today's top analyst calls »

Check out today's top…

IBM

IBM

$137.15

-0.85 (-0.62%)

PINS

Pinterest

$23.11

0.15 (0.65%)

EBAY

eBay

$35.69

-0.22 (-0.61%)

TWTR

Twitter

$34.11

-0.08 (-0.23%)

SNAP

Snap

$19.10

0.85 (4.66%)

QCOM

Qualcomm

$95.08

3.305 (3.60%)

WDC

Western Digital

$68.69

0.07 (0.10%)

LUV

Southwest

$55.31

0.01 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 28

    Jan

  • 30

    Jan

  • 04

    Feb

  • 05

    Feb

  • 06

    Feb

  • 06

    Feb

NCLH

Norwegian Cruise Line

$59.43

0.84 (1.43%)

11:21
01/17/20
01/17
11:21
01/17/20
11:21
Periodicals
Breaking Periodicals news story on Norwegian Cruise Line »

Hedgeye names Norwegian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
01/17/20
01/17
11:17
01/17/20
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
01/17/20
01/17
11:16
01/17/20
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$7.45

-0.49 (-6.17%)

11:15
01/17/20
01/17
11:15
01/17/20
11:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
01/17/20
01/17
11:10
01/17/20
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

STT

State Street

$84.45

3.445 (4.25%)

11:08
01/17/20
01/17
11:08
01/17/20
11:08
Periodicals
State Street held talks to find buyer for Currenex, FT reports »

State Street has held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 31

    Jan

  • 26

    Feb

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
U.S. equities are modestly firmer at fresh record highs »

U.S. equities are…

ERIC

Ericsson

$9.01

-0.075 (-0.83%)

10:55
01/17/20
01/17
10:55
01/17/20
10:55
Options
Ericsson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

10:55
01/17/20
01/17
10:55
01/17/20
10:55
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

JBLU

JetBlue

$19.30

0.28 (1.47%)

10:45
01/17/20
01/17
10:45
01/17/20
10:45
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

10:40
01/17/20
01/17
10:40
01/17/20
10:40
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

ES

Eversource

$87.74

0.01 (0.01%)

, CMS

CMS Energy

$65.28

-0.1 (-0.15%)

10:32
01/17/20
01/17
10:32
01/17/20
10:32
Downgrade
Eversource, CMS Energy, NextEra Energy rating change  »

NextEra, CMS Energy,…

ES

Eversource

$87.74

0.01 (0.01%)

CMS

CMS Energy

$65.28

-0.1 (-0.15%)

NEE

NextEra Energy

$251.86

-0.41 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 24

    Jan

  • 30

    Jan

  • 12

    Mar

  • 13

    Mar

TWTR

Twitter

$34.14

-0.05 (-0.15%)

, SNAP

Snap

$19.15

0.9 (4.93%)

10:31
01/17/20
01/17
10:31
01/17/20
10:31
On The Fly
Analysts bullish on Pinterest, Snap as Twitter gets downgraded to Neutral »

Shares of social media…

TWTR

Twitter

$34.14

-0.05 (-0.15%)

SNAP

Snap

$19.15

0.9 (4.93%)

PINS

Pinterest

$23.30

0.34 (1.48%)

FB

Facebook

$221.31

-0.47 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 04

    Feb

  • 06

    Feb

  • 06

    Feb

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Options
Busy week for 50 Cent as another massive block of calls is bought »

Busy week for 50 Cent as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

, KKR

KKR

$31.17

0.67 (2.20%)

10:30
01/17/20
01/17
10:30
01/17/20
10:30
Periodicals
KKR not discussing going hostile on Dave & Buster's, Axios reports »

KKR (KKR) has a…

PLAY

Dave & Buster's

$47.28

5.23 (12.44%)

KKR

KKR

$31.17

0.67 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 31

    Jan

  • 26

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.